Imugene Ltd
ASX:IMU
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (11.1), the stock would be worth AU$-3.64 (3 010% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | AU$0.13 |
0%
|
| Industry Average | 11.1 | AU$-3.64 |
-3 010%
|
| Country Average | 14.1 | AU$-4.6 |
-3 777%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| AU |
|
Imugene Ltd
ASX:IMU
|
39.6m AUD | -0.4 | -0.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 715.8 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 21.4 | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 22.8 | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 17.3 | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.9 | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.8 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 11.6 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 108.4 | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -83.5 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 14.7 | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.3 |
| Median | 14.1 |
| 70th Percentile | 24.1 |
| Max | 9 251.5 |
Other Multiples
Imugene Ltd
Glance View
Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The firm is engaged in developing immunotherapies that seeks to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness the body’s immune system against cancerous tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with care drugs and immunotherapies such as chimeric antigen receptor T cells (CAR T’s) for solid tumors. Its PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies for the treatment of cancers. Its clinical trial candidates include VAXinia (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
